Incremental in‑year savings

Second Half of 2025

no prior guidance

$5 million to $8 million in incremental in‑year savings " "

no prior guidance

Gross Margins

Second Half of 2025

no prior guidance

36%–37% "

no prior guidance

Cost Savings Program

Second Half of 2025

no prior guidance

$20 million cost savings program expected to deliver $5 million–$8 million incremental savings and a total run‑rate savings of $20 million by 2026 " "

no prior guidance

Capital Expenditures (CapEx)

Second Half of 2025

no prior guidance

2%–3% of sales "

no prior guidance

Effective Tax Rate

Second Half of 2025

no prior guidance

28%–29% "

no prior guidance

Adjusted EBITDA Margins

Second Half of 2025

no prior guidance

High teens as a percentage of sales "

no prior guidance

Organic Growth & Market Share Gains

In Q1 2025, Q4 2024 and Q3 2024, executives consistently discussed organic volume performance, modest declines in some regions as well as targeted new business wins and broad-based share gains – especially noting strong performance in Asia Pacific. " " " " " "

In Q2 2025, the company reported 2% year‐over‐year organic volume growth with sequential gains across all segments and strong, broad‐based market share gains (notably in Asia Pacific). " " " "

A consistent focus on driving organic growth and market share, with continued emphasis on Asia Pacific strength leading to improving performance.

Capital Allocation & Shareholder Returns

Previous discussions in Q1 2025, Q4 2024 and Q3 2024 emphasized a disciplined approach to capital allocation through a mix of share repurchases, dividend growth, and strategic acquisitions, with a balanced emphasis on M&A and organic investments. " " " " " "

In Q2 2025, the company repurchased $33 million in shares, increased its dividend by 5%, and completed acquisitions (e.g. Naytech and Dipsol), reinforcing a balanced capital allocation strategy. " " " "

Consistent execution with a continued balanced approach to deploying capital to drive growth and deliver shareholder value.

Margin & Cost Management

Across Q1 2025, Q4 2024 and Q3 2024, executives discussed margin pressures from raw material costs and manufacturing issues while implementing cost programs (e.g., $20 million cost program, SG&A reductions, restructuring actions) to drive margin improvement. " " " " " " " " " " "

In Q2 2025, despite gross margins being slightly lower at 36%, targeted pricing actions, cost reduction programs (including a $20 million cost program and a $9 million restructuring charge), and investments in manufacturing are expected to support gradual margin improvement. " " " "

The sentiment is shifting from pressure toward improvement as cost optimization initiatives and targeted pricing actions start to bear fruit.

Supply Chain Resilience & Dual Sourcing

In Q1 2025, executives highlighted dual sourcing and local production to mitigate tariff impacts, while Q3 2024 briefly touched on broader supply chain and manufacturing enhancements. " "

In Q2 2025, there was no mention of supply chain resilience or dual sourcing strategies.

This topic, previously mentioned for its role in mitigating disruptions, is no longer referenced in the current period.

Strategic Acquisitions & Integration

In Q1 2025, Q4 2024 and Q3 2024, the company detailed strategic acquisitions (e.g. Dipsol, CSI, IKV, SUTAI) and their integration to expand market access, drive advanced solutions and enhance operational scale. " " " " " " " "

In Q2 2025, executives discussed completing acquisitions such as Dipsol and Naytech, emphasizing the integration of new technologies and local-for-local strategies to drive growth, particularly in Asia Pacific. " " "

Consistent focus on strategic acquisitions with ongoing integration activities that are increasingly viewed as key levers to capture market opportunities and drive growth.

Tariff, Geopolitical & Macroeconomic Uncertainty

In Q1 2025, executives mentioned tariffs, geopolitical events and macroeconomic softness as challenges impacting raw material costs, demand, and end-market volatility. " " " Q3 2024 and Q4 2024 provided little or no detail on these topics.

In Q2 2025, comprehensive discussions highlighted tariffs affecting cost structures and geographical mixes, along with persistent geopolitical volatility contributing to regional goodwill impairments and caution in customer behavior. " " " " "

Persistent external headwinds remain a central concern, and the focus on how these uncertainties affect both cost inputs and market demand appears slightly heightened in the current period.

Regional Demand Volatility & Performance

Q1 2025, Q4 2024 and Q3 2024 consistently noted regional disparities – with strong organic performance and new business wins in Asia Pacific, offset by softness and volatility in the Americas and EMEA. " " " " " " " "

Q2 2025 continued this narrative, with Asia Pacific demonstrating robust growth and sequential gains, while the Americas and EMEA experienced modest declines in sales or volume. " "

The regional divergence in performance remains consistent, with Asia Pacific emerging as a robust growth area even as softness in other regions persists.

Raw Material Cost & Pricing Pressure

Throughout Q1 2025, Q4 2024 and Q3 2024, discussions centered on higher raw material and manufacturing costs, index-based pricing challenges and the need for selective price increases to manage margin pressures. " " " " " " " " "

In Q2 2025, executives reported slightly lower gross margins (36%) due to higher raw material and manufacturing costs compounded by tariffs, along with ongoing measures (targeted pricing actions and cost programs) to mitigate these pressures. " " "

Persistent pricing and cost pressures remain a challenge, with proactive measures in place to manage these issues, though the overall sentiment remains cautious.

FX & Currency Risks

FX impacts were discussed in Q1 2025, Q4 2024 and Q3 2024 – highlighting unfavorable impacts on net sales and adjusted EBITDA (ranging from 1% to 3% adverse effects). " " " " "

In Q2 2025, there is no mention of FX or currency risks.

This topic, previously noted as a headwind, is not mentioned in the current period, suggesting it may be less of a focus or better managed than before.

Advanced Product Innovation & Strategic Investments

In Q1 2025, Q4 2024 and Q3 2024, initiatives like the FLUID INTELLIGENCE platform, new manufacturing facilities (including a plant in China) and digital/simplification efforts were discussed as ways to enhance value and competitiveness. " " " " "

In Q2 2025, new investments are highlighted – particularly progress with the Fluid Intelligence platform and the build-out of a new facility in China – reinforcing a strategy focused on advanced product offerings and enhanced efficiency. " " " "

There is a sustained emphasis on innovation and strategic investments, with consistent efforts to drive new growth through technology and capacity expansion.

Execution Risks in Growth Initiatives & CapEx

Across Q1 2025, Q4 2024 and Q3 2024, the company discussed disciplined capital allocation, the importance of synchronizing acquisitions and organic growth, and the challenges of executing large-scale projects while managing cost programs. " " " " " " " " " "

In Q2 2025, detailed commentary was provided on execution risks, including the timing and budgeting risks related to new facility CapEx in China, the implementation of cost savings initiatives, and balancing growth with financial flexibility. " " " "

Execution risks remain a key focus, with ongoing efforts to proactively manage CapEx and growth initiatives despite market uncertainties and implementation challenges.

Noncash Charges & Goodwill Impairment

This topic was not mentioned in Q1 2025, Q4 2024 or Q3 2024 earnings calls.

In Q2 2025, a noncash goodwill impairment charge in the EMEA segment was disclosed, attributed to persistent market volatility and geopolitical events. "

A new topic emerging in the current period, highlighting the impact of external uncertainties on asset values and adding a one‐time noncash charge to the financials.

Seasonal Weakness

Seasonal factors were consistently discussed in Q1 2025, Q4 2024 and Q3 2024, noting expected downturns (e.g., post-Lunar New Year in Asia Pacific, and traditional seasonal softening in the Americas/EMEA) along with expectations of sequential improvements later in the year. " " " " " " " "

In Q2 2025, executives referenced seasonal weakness by noting typical declines in certain regions (e.g., anticipated in Q4 for Europe and the Americas) while highlighting relatively steadier performance in Asia Pacific. " "

Seasonal trends remain a predictable, recurring theme – with acknowledged weaknesses in some regions balanced by recovery expectations in subsequent quarters.